2 results
Approved WMORecruiting
The objectives of this trial are:1. To define the performance characteristics of FDHT PET in patients with metastasized castrate resistant prostate cancer(mCRPC).(a) To demonstrate the kinetics of displacement of the tracer off of the androgen…
Not approvedWill not start
This clinical performance study will evaluate the effectiveness of the Ki 67 IHC MIB-1 pharmDx (Dako Omnis) to identify estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- early breast cancer patients whose tumours score Ki-67…